The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials

Conclusion: This meta-analysis indicates that the addition of onartuzumab to the standard treatments had no definite survival benefit with increased severe toxicities in patients with solid cancer.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research